IL-10 production by the cAMP-elevating agonist prostaglandin E 2 (PGE 2 ) (21). 84
Although less pronounced, AKAP11 also plays a modulatory role in the above-85 mentioned processes (21). 86 added 10 minutes after the addition of st-Ht31. The action of these cAMP 147 analogues has previously been characterized in this system (29). Cells were 148 stimulated with 15% CSE for different time points: 10 min for VASP 149 phosphorylation, 1 h for ERK phosphorylation, 2 h for nuclear factor-κB (NF-κB) 150 translocation and 24 h for AKAP mRNA and protein expression and ELISA 151 measurements of IL-8. Serum-free medium (vehicle) served as control for all 152 experiments, as st-Ht31P, the commonly used control for st-Ht31, has been 153 reported to be a direct inhibitor of PKA (24). In addition, st-Ht31P decreased cell 154 viability in a dose-dependent manner ( Figure 6E ), rendering st-Ht31P invalid as 155 a control in this set-up, and in line with previous observations from our group 156 (28). 157 RII overlay -RII overlay assay was performed as described previously (14, 158 18). In brief, proteins were subjected to SDS-PAGE, transferred to PVDF 159 membranes and incubated in RII blocking buffer (5% milk powder, 0.1% BSA, 160 0.1% sodium azide in PBS) for three hours at room temperature. The 161 membranes were incubated with [γ Real time PCR -After 24 hours, total RNA was isolated using the 184 NucleoSpin® RNA II isolation kit (Machery-Nagel) and cDNA was obtained using 185 the Reverse Transcription System (A3500, Promega) following the 186 manufacturers' instructions. This cDNA was used as a template for quantitative 187 real time PCR for AKAP5 (Forward; 5'-GACGCCCTACGTTGATCT-3', Reverse; 188 Immunofluorescence -Cells were seeded on coverslips, and after 24 216 hours put to serum free conditions overnight, they were stimulated for 2 hours. 217
After stimulation cells were fixed in 3% paraformaldehyde (PFA) for 15 minutes, 218 subsequently 3% PFA and 0.3% Triton X-100 were added. Blocking was 219 performed (1% BSA and 2% donkey serum in CytoTBS-T for 1 h) followed by 220 incubating in a humidifying chamber with the primary antibody against p65 (1:20 221 in blocking solution) at 4 °C. Nuclei were stained with a Hoechst staining 222
(1:10000). ProLong Gold antifade reagent was added to mount the cells before 223 cells were visualized. Co-localization of p65 with nuclear staining was quantified 224 using Tissuefaxs (TissueGnostics GmbH). Figure 1A ). Pre-incubation of RIIα subunits with the 240 that CSE-induced IL-8 release was dose-dependently attenuated by the β 2 -284 agonist, fenoterol, with a maximum reduction of 50% being reached with 0.1 µM 285 fenoterol (p<0.01; Figure 6A ). The PKA activator 6-Bnz (500 μM) also reduced 286 CSE-induced IL-8 release by about 50% ( Figure 6B ). Similarly, as we observed 287 previously (26), selective pharmacological activation of Epac with 8-pCPT (100 288 μM) decreased CSE-induced IL-8 release (p=0.07, Figure 6B) . 289
To determine the role of AKAP-PKA interactions in CSE-induced IL-8 290 release and in the inhibitory effects of the β 2 -agonist fenoterol, the PKA activator 291 6-Bnz, and the Epac activator 8-pCPT, we next measured the impact of the cell-292 permeant PKA anchoring disruptor peptide, st-Ht31. The control peptide st-293
Ht31P could not be used as a control, since it caused death of the ASM cells The more limited effectiveness of Epac activation with 8-pCPT is most likely dueHt31, possibly because the phospho-ERK1/2 level was already at its maximum. 364
With the observation that, in contrast to ERK1/2 phosphorylation, CSE-induced 365 IL-8 release is further enhanced with the addition of st-Ht31, it is possible that 366
another AKAP-PKA sensitive pathway is involved in IL-8 release. For example 367 other studies have identified that p38-and JNK-induced signaling pathways can 368 regulate the release of IL-8 (42), and that these kinases could also be affected by 369
PKA . 370
A role for AKAPs in coordinating the duration of cAMP production after 371 stimulation of the β 2 -adrenoceptor has been shown in several cell types, 372 including ASM cells transfected with a cyclic nucleotide gated ion channel-based 373 reporter (15). In that study, disruptors of AKAP-PKA interactions, Ht31 and 374 AKAP-IS, did not cause a change in whole cell cAMP accumulation after 375 stimulation with the β 2 -agonist isoprenaline or forskolin, a direct activator of 376 cAMP producing adenylyl cyclases (31). However, the duration of the transient 377 local cAMP signal measured at the plasma membrane was significantly 378 sustained by AKAP-PKA interaction disruptors (15). It was shown that AKAP12 is 379 responsible for resensitization and recycling of the β 2 -adrenoceptor after 380 treatment with isoproterenol, whereas AKAP5 is responsible for PKA mediated 381 β 2 -adrenoceptor phosphorylation and subsequent switching from the cAMP 382 pathway to β-arrestin-ERK1/2 signaling (5, 11, 22, 32, 39). Therefore, the altered 383 expression of AKAP5 after exposure to CSE and in COPD might have important 384 consequences for ERK1/2 in IL-8 signaling. 385
We observed that CSE causes a downregulation of AKAP5 and AKAP12 386 mRNA and protein in both immortalized and primary ASM cells, suggesting aalterations in AKAP expression may contribute to increased IL-8 release from 390 ASM. We also observed the downregulation of AKAP5 and AKAP12 mRNA in 391 lung tissue from COPD patients, suggesting roles of these AKAPs in β 2 -392 adrenoceptor responses. Previously, it was observed in BeWo trophoblast cells 393 that a common pathway may regulate expression of AKAP5 and AKAP12 protein 394 and mRNA, which is different from that of AKAP8 mRNA regulation (9). Along 395 these lines, in the current study, we observed that CSE reduced AKAP5 and 396 AKAP12 mRNA expression, while AKAP8 was not affected. 397
In addition to ASM, we observed high expression of AKAP5 and AKAP12 in 398 airway epithelium. Recently, we showed (25), in contrast to our current findings in 399 
